nference Establishes AI Research Partnership with Parabilis Medicines in Colorectal Cancer

Figure 1 - nferX Signals app query for "Adenovirus AND Receptor" across the core corpus (PubMed, Preprints, Clinical Trials, SEC filings, Patents etc) shows CXADR gene as strongest candidate for viral receptor from published biomedical literature.

Figure 2B - nferX Proteomics app shows that CXADR protein is also expressed at lower levels of enrichment in the respiratory tract (e.g. saliva, lungs) as well as the gastrointestinal system (e.g. colon, rectum)

Figure 2C - nferX Proteomics app details show 9 different mass spectrometry studies as all displaying normal and diseased liver tissues with enriched CXADR protein levels.

Figure 2D - nferX Proteomics app helps dive into 1 of the 9 individual studies with Mass Spec data, showing CXADR significantly expressed in 223 of 248 liver samples from both non-tumor (healthy) liver as well as hepatocellular carcinoma liver samples.

Figure 2E - nferX Proteomics app shows fetal brain and heart tissues  express the CXADR protein from mass spectrometry data suggesting pediatric population may also express CXADR protein in these tissues.

Figure 2F - nferX Proteomics app shows fetal liver, heart and ovary tissues express the CXADR protein from mass spectrometry data suggesting pediatric population may also express CXADR protein in these tissues.

Figure 3. nferX proteomics app has an immunohistochemistry (IHC) panel that shows that liver tissue stains moderately with a CXADR antibody (Source: Imaging data from Human Protein Atlas - HPA).

Figure 4a - nferX Single Cell app shows that Hepatic stem cells and Cholangiocytes have one of the most significant expression levels for the CXADR gene.

Figure 4b - nferX Single Cell app enables comprehensive profiling of over 3 million single cell RNA-seq (scRNAseq) human samples and provides distribution of 310K+ cell samples with non-zero expression of CXADR gene. This result shows that both the respiratory tract (nasal cavity, lungs) as well as gastrointestinal system (large intestine, small intestine) have cell types expressing the CXADR gene.

Figure 5a - nferX RNA Explorer app enables comparison of cohorts across studies for CXADR gene expression. Here Group A has White ethnicity samples (n = 6497) from 118 studies, being compared with Group B with 7 studies of African American/Black and Hispanic/Latino individual's samples (n=124).

Figure 5b - nferX RNA Explorer app shows individuals in Group B (African American/Black or Latino/Hispanic ethnicity) having modestly more expression of CXADR gene than Group A (White ethnicity) with Cohen's D value of 1.06 (effect size).

Comprehensive molecular profiling of Adenovirus receptor (CXADR) by the nference platform reveals strong expression in liver tissues: Implications for rising pediatric hepatitis cases in Europe and North America

Adenovirus infection and pediatric hepatitis: Pan-tissue molecular profiling of Adenovirus receptor (CXADR) protein reveals strong liver expression

nference | Adenovirus infection and pediatric hepatitis: Pan-tissue molecular profiling of Adenovirus receptor (CXADR) protein reveals strong liver expression

Unlock actionable insights to improve patient outcomes and optimize healthcare delivery with data-driven solutions.

For Health Systems

With our partners - industry leaders, innovators and leading institutions - we’re delivering real-world data insights and shaping transformative solutions in healthcare.  

Harness diverse real-world data types to gain insights across genomic, clinical, and operational dimensions

Data Modality

Transform fragmented datasets into cohesive narratives, enabling meaningful insights and impactful healthcare advancements.

Data Synthesization

nference’s platform and tools transform real world data into actionable insights for healthcare innovation.

Streamline research with AI-powered tools that transform complex data into actionable medical insights

For Clinical Researchers

Access advanced datasets and cutting-edge analytics to power innovation in healthcare and life sciences.

For Data Scientists

nSights turns complex healthcare data into actionable insights, driving innovation and smarter decision-making in medical research and development.

Revolutionize drug development through AI-driven insights, accelerating timelines and improving clinical trial outcomes.

For Bio Pharma

Empower device innovation with robust data integration and advanced analytics for regulatory and market success.

Medical Devices

Our AI-driven solutions empower clinical trial design, enhance innovation in product development and streamline regulatory submissions.

Characterization of Patients With Narcolepsy Treated vs Not Treated With Sodium Oxybate: A Propensity Score–Matched Cohort Study

Associations of the Fibrosis-4 Index With Rates of Cardiac Events and Liver Decompensation, and the Potential Implications on Risk Stratification in Patients With Nonalcoholic Steatohepatitis.

Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence

{
"Electrocardiograms": "",
"Gastro-intestinal": "",
"Cardiology": "",
"Metabolic Diseases": "",
"Real-world Effectiveness": "",
"Epidemiology": "",
"Covid-19": "",
"Oncology": "",
"Hepatology": "",
"Mesothelioma": "",
"NSCLC": "",
}

nference's extensive library of publications showcase cutting-edge research and healthcare advancements.

Blogs

nference Establishes AI Initiative with Takeda to Advance Precision Medicine in Inflammatory Bowel Disease

News

Our latest blogs and insights cover industry trends, technological breakthroughs, and expert insights, to keep you updated on the forefront of healthcare innovation.

Cutting-edge AI solutions to transform cardiac care

Empowering digital pathology with a new WSI paradigm